FDA Clears Dyne's IND for FSHD Drug, Third Program Enters Clinic
DYN has more than doubled off its 52-week low of $8.88.
Summary
Dyne Therapeutics received FDA clearance to start a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD), a rare muscle-wasting disease with no approved therapies. This is the company's third clinical program using its FORCE platform, following z-rostudirsen in DMD and z-basivarsen in DM1. The trial will enroll 9 adults in a multiple ascending dose study, with a primary focus on safety and tolerability, and includes a 96-week extension. Preclinical data showed robust DUX4 knockdown and functional improvement, supporting a differentiated profile. The news comes just days after Dyne priced a $375M follow-on offering at a discount, and follows the recent FDA acceptance of its BLA for z-rostudirsen with Priority Review. Expanding the pipeline into FSHD adds a new, high-value indication and reinforces the platform's potential, though clinical data is still early.
At the time of this announcement, DYN was trading at $25.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $8.88 to $26.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.